Connect Biopharma Limite... (CNTB)
Connect Biopharma Statistics
Share Statistics
Connect Biopharma has 55.25M shares outstanding. The number of shares has increased by 0.27% in one year.
| Shares Outstanding | 55.25M |
| Shares Change (YoY) | 0.27% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 5.77% |
| Shares Floating | 14.82M |
| Failed to Deliver (FTD) Shares | 1.92K |
| FTD / Avg. Volume | 5.17% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -4.88 and the forward PE ratio is null. Connect Biopharma's PEG ratio is 0.07.
| PE Ratio | -4.88 |
| Forward PE | n/a |
| PS Ratio | 2.93 |
| Forward PS | 0.7 |
| PB Ratio | 0.83 |
| P/FCF Ratio | -3.13 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Connect Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.46, with a Debt / Equity ratio of 0.
| Current Ratio | 11.46 |
| Quick Ratio | 11.46 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $321.4K |
| Profits Per Employee | $-192.94K |
| Employee Count | 81 |
| Asset Turnover | 0.26 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 223K |
| Effective Tax Rate | -1.45% |
Stock Price Statistics
The stock price has increased by -67.22% in the last 52 weeks. The beta is -0.22, so Connect Biopharma's price volatility has been lower than the market average.
| Beta | -0.22 |
| 52-Week Price Change | -67.22% |
| 50-Day Moving Average | 0.86 |
| 200-Day Moving Average | 1.11 |
| Relative Strength Index (RSI) | 31.81 |
| Average Volume (20 Days) | 37.08K |
Income Statement
In the last 12 months, Connect Biopharma had revenue of 26.03M and earned -15.63M in profits. Earnings per share was -0.28.
| Revenue | 26.03M |
| Gross Profit | 26.03M |
| Operating Income | -22.45M |
| Net Income | -15.63M |
| EBITDA | -22.45M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.28 |
Balance Sheet
The company has 78.23M in cash and 178K in debt, giving a net cash position of 78.05M.
| Cash & Cash Equivalents | 78.23M |
| Total Debt | 178K |
| Net Cash | 78.05M |
| Retained Earnings | -345.36M |
| Total Assets | 120.57M |
| Working Capital | 106.27M |
Cash Flow
In the last 12 months, operating cash flow was -23.61M and capital expenditures -750K, giving a free cash flow of -24.36M.
| Operating Cash Flow | -23.61M |
| Capital Expenditures | -750K |
| Free Cash Flow | -24.36M |
| FCF Per Share | -0.44 |
Margins
Gross margin is 100%, with operating and profit margins of -86.24% and -60.03%.
| Gross Margin | 100% |
| Operating Margin | -86.24% |
| Pretax Margin | -59.17% |
| Profit Margin | -60.03% |
| EBITDA Margin | -86.24% |
| EBIT Margin | -86.24% |
| FCF Margin | -93.58% |
Dividends & Yields
CNTB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CNTB is $8, which is 1255.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 1255.9% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -5.94 |
| Piotroski F-Score | 4 |